Close yesterday .44/.47:
Company Press Release
Pathobiotek Launches New Website
HOUSTON--(BUSINESS WIRE)--March 11, 1999--Pathobiotek Diagnostics, Inc.
(OTC BB:PBTK - news), a developer of diagnostic products for the treatment of
multiple
sclerosis (MS) and other immune disorders, today announced the Company has
launched a
new web site. www.pathobiotek.com provides current news releases and Company
information for the investor and medical
communities.
''This sophisticated, user-friendly and high-end web site will help further Pathobiotek's
overall recognition,'' stated Robert
Simpson, President and CEO of Pathobiotek. ''Additionally, we intend to use the
website as an information center for our
shareholders, customers and collaborators. Information will be upgraded more
frequently than in the past allowing the reader to
view the Company's progress as the news becomes available. A non-confidential
product brochure will be available soon, as
well as a more complete picture of our technology.''
Pathobiotek is a research and development Biotechnology Company dedicated to
developing, producing and licensing
diagnostics for multiple sclerosis (MS) and other immune disorders.
Safe Harbor Statement: Except for historical information contained herein, the matters
set forth in this news release are
forward-looking statements. Forward-looking statements involve certain risks and
uncertainties that could cause actual results
to differ materially from expectations. Factors that could contribute to such differences
include those identified in the Company's
filings with the Securities and Exchange Commission.
Contact:
DeMonte Associates, New York
Cynthia DeMonte, 212/473-3700
cdemonte@aol.com
Pathobiotek Reports MRL Inc. Progressing in the
Development of Immunoassays
Collaboration Commenced January 15, 1999
HOUSTON--(BUSINESS WIRE)--March 1, 1999--Pathobiotek Diagnostics, Inc.
(OTC BB:PBTK - news), a developer of
diagnostic products for the treatment of multiple sclerosis (MS) and other immune
disorders, today announced that the licensing
agreement with MRL, Inc. is seen as promising by MRL Inc., a widely recognized
leader in the development of emerging
technologies, specifically for infectious diseases.
MRL Inc. is progressing toward certain immunoassays to be used in pilot studies of
correlations between the Pathobiotek
organism, (Operational name: LUEY) MS and other diseases. Pilot studies will produce
epidemiological data that will serve as
the foundation for further product development and subsequent sale of Pathobiotek
diagnostic products by MRL Inc. as
specified in the license agreement.
MRL Inc. will use Pathobiotek technology for immunological and neurological markers
for MS and other diseases. Since they
are involved with leading neurologists and scientists they have access to extensive
clinical data and specimens. MRL Inc. is
developing immunoassays and western blots, which allow for the accumulation of
epidemiological information as well as
identification of markers associated with the Pathobiotek organism and various diseases.
According to Dr. Richard Porschen, Director, MRL Inc. ''I view the PDI technology
with much excitement and enthusiasm. I
hope to develop cost effective and practical diagnostic assays, which can be used for
the diagnosis of diseases associated with
the proprietary Pathobiotek material. I am pleased MRL Inc. has added the
Pathobiotek technology to its MS program.'' MRL
Inc.'s website is www.drwatson.com.
Robert Simpson, President & CEO of Pathobiotek, stated, ''As we move our products
through the development pipeline and
prepare for marketing and commercialization, licensing agreements of this nature are
vital. The Company continues its
momentum of gaining interest in future products and thereby building value for the
LUEY technology platform. MRL possesses
the unique ability to offer novel tests through its specialized clinical laboratory, prior to
the development of an FDA approved
product. This allows for financial gains for Pathobiotek much earlier in the product
development cycle,'' Simpson concluded.
Pathobiotek is a research and development Biotechnology Company dedicated to
developing, producing and licensing
diagnostics for multiple sclerosis (MS) and other immune disorders.
Pathobiotek Enters Licensing Negotiations With
International Pharmaceutical Company With Revenues
in Excess of $2.5 Billion
Company Expects to Commence Collaboration With MRL by January
18th
HOUSTON--(BUSINESS WIRE)--Jan. 11, 1999-- Pathobiotek Diagnostics, Inc.
(OTC BB:PBTK - news), a developer of
diagnostic products for the treatment of multiple sclerosis (MS) and other immune
disorders, today announced that the
Company has entered into licensing negotiations with a publicly-traded international
pharmaceutical company with annual
revenues in excess of $2.5 billion, for one of its diagnostic products. Pathobiotek will
announce further detail upon the signing of
a Letter of Intent.
Additionally, the Company announced that it expects that the forthcoming licensing
agreement with privately-held,
California-based, MRL, Inc. will be signed in time to allow collaborative efforts to begin
by the week of January 18, 1999.
MRL, Inc. (www.drwatson.com), is widely recognized for the development of emerging
technologies, specifically, in infectious
diseases. As previously announced, Pathobiotek expects to generate in excess of $3
million in revenues through this alliance.
Robert Simpson, President & CEO of Pathobiotek, stated, ''As we move our products
through the pipeline and prepare for
marketing and commercialization, these licensing agreements are of vital importance.
The interest the Company is gaining in its
proprietary technologies from major private and public established diagnostics
organizations lends great credibility to not only
technologies, but our potential for the future.''
------
Previous
|
